Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.00
Bid: 13.50
Ask: 14.50
Change: -0.25 (-1.75%)
Spread: 1.00 (7.407%)
Open: 14.25
High: 14.00
Low: 13.75
Prev. Close: 14.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Contract Extension

24 Jan 2006 07:01

Angle PLC24 January 2006 For Immediate Release 24 January 2006 ANGLE plc Contract Extension: Innovation Support Project with the London Development Agency ANGLE plc, the venture management and consulting company specialising in thecommercialisation of technology is pleased to announce that it has won acontinuation of the SME Innovation Support Project with the London DevelopmentAgency for a further two years. The project extension has a total contract valueof £2.2 million, of which £800,000 is ANGLE fees with the balance being grantsto companies and project expenditure. The contract extension runs from January2006 for 27 months. The extension of the SME Innovation Support Project, which is part-funded by theEuropean Regional Development Fund, builds on the successful delivery ofconsulting work provided by ANGLE to over 50 SME organisations. The aim is nowto work with over 150 companies to generate over 50 products, stimulatinginnovation within the London Objective area by providing easier access toexpertise, particularly from London's universities and research institutions. The Innovation Support Project also addresses local needs by increasingcompetitiveness of SMEs through improved innovation and technology assistance.Specifically, it aims to: • Raise understanding of innovation and the benefits it can bring to abusiness; • Help SMEs to identify innovation needs and opportunities; • Facilitate links to sources of innovation and knowledge and supportthe transfer and exploitation of knowledge; • Provide small scale grant funding to encourage SMEs to implement andexploit identified knowledge and innovation opportunities; • Encourage collaborative innovation and technology transfer betweenacademic and research institutions and business; • Build on the success of the current project to develop a pan-Londondelivery model. Andrew Newland, Chief Executive of ANGLE plc said: "We are delighted to have been awarded this significant contract extension,which highlights the success that we are presently experiencing in our UKconsulting business and strengthens our platform for ventures activity." For further information ANGLE plc +44 1483 295830Andrew Newland, Chief ExecutiveIan Griffiths, Finance Director Buchanan Communications +44 20 7466 5000Richard Darby, Suzanne Brocks, James Strong Note to editors: About ANGLE Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE operates from officesin the UK, the US and the Middle East. ANGLE is listed on AIM (AGL.L); further information can be found atwww.angleplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Jul 20147:00 amRNSNotification of Preliminary Results
29th Apr 20144:30 pmRNSHoldings in Company
8th Apr 20147:00 amRNSIntellectual Property Update
24th Mar 20147:00 amRNSAppointment of Scientific Adviser
17th Mar 20147:00 amRNSParsortix FDA Submission
24th Feb 20147:00 amRNSUse of Parsortix System with Liver Cancer Patients
18th Feb 20147:00 amRNSParsortix Launch at Circulate Conference in Berlin
30th Jan 20147:00 amRNSInterim Results
13th Jan 20147:00 amRNSCambridge Parsortix Laboratory
10th Jan 20147:00 amRNSNotification of Interim Results and Webcast
7th Jan 20147:00 amRNSAppointment of Scientific Adviser
17th Dec 20137:00 amRNSCE Mark Authorisation
13th Dec 20137:00 amRNSRaises £6.2m from Sale of Geomerics
31st Oct 20133:31 pmRNSResult of 2013 Annual General Meeting
9th Oct 20137:00 amRNSAnnual Report and Accounts and Notice of AGM
31st Jul 20137:00 amRNSPreliminary Results
25th Jul 20137:00 amRNSPositive Evaluation of Parsortix System
19th Jul 20137:00 amRNSNotification of Preliminary Results and Webcast
8th Jul 20137:00 amRNSParsortix Colorectal Cancer Validation
29th May 20137:00 amRNSDirector's Share Transfer
28th May 20137:00 amRNSParsortix Manufacturer Appointed
13th May 20137:00 amRNSPARSORTIX CELL HARVESTING
7th May 20137:00 amRNSParsortix Regulatory Approval Update
28th Feb 20137:00 amRNSParsortix Research Product Launch
15th Feb 201310:56 amRNSDirector's share transfer
31st Jan 20137:01 amRNSFundraising and Director's Dealings
31st Jan 20137:00 amRNSInterim Results
16th Jan 20137:00 amRNSNotification of Interim Results and Webcast
14th Jan 20137:00 amRNSParsortix Cell Recovery
7th Jan 20137:00 amRNSAppointment of NED
18th Dec 20127:00 amRNSParsortix Released to Research Partners
10th Dec 20127:00 amRNSBUSINESS UPDATE
18th Oct 20127:00 amRNSAppointment of Scientific Advisers
17th Oct 20123:45 pmRNSHolding(s) in the Company
11th Oct 20123:39 pmRNSResult of 2012 Annual General Meeting
3rd Sep 20127:00 amRNSIncreased Fundraising
1st Aug 20127:00 amRNSIncreased Fundraising
26th Jul 20127:01 amRNSFundraising
26th Jul 20127:00 amRNSPreliminary Results
24th Jul 20127:00 amRNSNotice of Preliminary Results and Conference Call
27th Jun 20127:00 amRNSOffer Unconditional for Novocellus' Partner Origio
7th Jun 20127:00 amRNSUpdate Re Novocellus' Partner ORIGIO A/S
16th May 20127:00 amRNSGeomerics Milestone Payment
30th Apr 20127:00 amRNSParsortix Design Breakthrough
26th Apr 20127:00 amRNSLaunches New Corporate Website
23rd Apr 20127:00 amRNSParsortix Update for Breast Cancer
17th Apr 20127:00 amRNSParsortix Validation for Ovarian Cancer
11th Apr 20127:00 amRNSNovocellus Embryosure® Trial Started
26th Mar 20127:00 amRNSGeomerics Update
15th Mar 20127:00 amRNSParsortix Validation for Colon Cancer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.